VICTRELIS™ (boceprevir), first-in-class oral hepatitis C virus protease inhibitor, approved in the European Union
18 July 2011 | By Merck
The European Commission approved VICTRELIS™ (boceprevir)...
List view / Grid view
News
New data showed minimal potential for drug interaction between cholesterol drug LIVALO® and a common antiretroviral therapy
18 July 2011 | By Eli Lilly and Company
New study results released...
Merck’s ISENTRESS® (raltegravir) in combination therapy demonstrated efficacy in a Phase II Study
18 July 2011 | By Merck
Extending to nearly five years in previously untreated adults with HIV-1...
Amgen resolves G-CSF patent litigation With Teva
15 July 2011 | By Amgen
Amgen announced that the U.S. District Court in Pennsylvania has entered final judgment and a permanent injunction against TEVA...
XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
15 July 2011 | By Amgen
The European Commission has granted marketing authorization for XGEVA® (denosumab)...
Abbott confirms long-term commitment to HIV care with the planned development of new formulations
15 July 2011 | By Abbott
Abbott plans to develop two new formulations of its HIV medicines...
Novartis begins shipment of Fluvirin®
15 July 2011 | By Novartis
Novartis announced that the Company has started shipping seasonal influenza vaccine to its US customers for the 2011-2012 influenza season...
Janssen Pharmaceuticals, Inc. announces definitive agreement to divest Ortho Dermatologics Division
15 July 2011 | By Janssen Pharmaceuticals Inc
Janssen Pharmaceuticals, Inc. announced a definitive agreement to divest the assets of its Ortho Dermatologics division...
Pertuzumab combined with Herceptin and chemotherapy significantly extended the time people with HER2-positive metastatic breast cancer lived without their disease getting worse
15 July 2011 | By Roche
Roche plans to seek approval with Health Authorities based on encouraging results...
ICON acquires Firecrest Clinical
14 July 2011 | By ICON plc
ICON plc, announced the acquisition of Firecrest Clinical, a market-leading provider of technology solutions that boost investigator site performance and study management...
Cephalon shareholders approve acquisition by Teva
14 July 2011 | By Cephalon Inc.
Cephalon, Inc. announced that its stockholders voted to approve the TEVA proposal to acquire Cephalon...
Novo Nordisk gains EU approval for FlexTouch®
14 July 2011 | By Novo Nordisk
Novo Nordisk has been granted approval by the European Commission for the new prefilled insulin pen – FlexTouch®...
YERVOY™ (ipilimumab) approved for the treatment of previously-treated advanced melanoma in the EU
14 July 2011 | By Bristol-Myers Squibb
The European Commission has approved YERVOY™ (ipilimumab)...
Gilead expands access program for medications in developing world
12 July 2011 | By Gilead Sciences
Gilead Sciences, Inc. announced an expansion of its global access program...
Sanofi and Regeneron report positive Phase 2b trial results with sarilumab in rheumatoid arthritis
12 July 2011 | By Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. announced results from Phase 2b trials...
